The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes

NCT01595789 on ClinicalTrials.gov · last registry update 2017-03-07

Finished October 2014, after enrolling 41 people. Primary outcome, as filed: Beta-cell function. liraglutide is already approved in the US for cardiovascular disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Haugaard, Steen Bendix, M.D., DMSc
Sponsor type: Indiv
Enrollment: 41
Started: 2012-05
Primary completion: 2014-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Beta-cell function

Conditions studied

Coronary Artery Disease · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.